Innocare Pharma Ltd (INCPF) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Innocare Pharma Ltd. Class A.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.858 -- 00:00:04.540 Great. Good morning and good evening, our global investors. 00:00:04.540 -- 00:00:08.823 Thank you for joining InnoCare 2025 Annual Results Earnings Call. 00:00:08.823 -- 00:00:12.256 This is Yisheng Chen, China healthcare analyst at Goldman Sachs. 00:00:12.256 -- 00:00:15.579 Before we kick off the session, I would like to highlight that this call is strictly 00:00:15.579 -- 00:00:19.441 for clients of Goldman Sachs and InnoCare only and this conversation is not intended 00:00:19.441 -- 00:00:24.284 for the media and is off the record. Participants will be removed from the call if they 00:00:24.284 -- 00:00:28.587 cannot be properly identified. This call on webcast is not for the purpose of sharing 00:00:28.587 -- 00:00:30.849 or receiving the public 00:00:30.849 -- 00:00:35.272 otherwise confidential information. Attendees are public side market participants who 00:00:35.272 -- 00:00:39.515 may not receive and should not request non-public or otherwise confidential information 00:00:39.515 -- 00:00:42.615 about issuers or securities 00:00:44.078 -- 00:00:49.503 Today, we're very honored to have the full team join the call to discuss 00:00:49.503 -- 00:00:54.527 the 2025 results and, of course, the outlook for 2026. 00:00:54.527 -- 00:00:57.850 So join us, including the chairperson and the CEO, Dr. 00:00:57.850 -- 00:01:03.174 Jasmine Cui, the CFO, Mr. Xingfu, CTO, Dr. 00:01:03.174 -- 00:01:07.478 Xiangyang Chen, and also SVP of Clinical Development, Dr. 00:01:07.478 -- 00:01:09.319 Red Bean So 00:01:09.319 -- 00:01:11.319 management 00:01:14.141 -- 00:01:16.441 is going 00:01:18.323 -- 00:01:21.184 to give 00:01:22.286 -- 00:01:27.528 us a prepared remarks and after that I'm going to convert it into a Q&A 00:01:27.528 -- 00:01:32...